FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/29/2024
Back to search
Official data from USPTO
BIOMADVANCED DIAGNOSTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079316363Class
5, 10, 35, 42, 44
Filing
79316363
Registration
7265167
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
04/29/2024
Trademark type
Combined
Nice classes
5, 10, 35, 42, 44
Filing date
04/21/2021
Registration date
01/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/09/2024
Last transaction
01/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
HARMON, RAYMOND
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the black stylized wording "BIOMADVANCED" above the smaller orange stylized wording "DIAGNOSTICS", with a large design of a curved arrow coming from the bottom-left of the mark to the upper-right of the mark. The design of the arrow begins as brown and fades to orange moving from left to right.
Holders and representatives
Holders
B. D. (pessoa física)
AGFPR HOLDING
F. P. (pessoa física)
Representatives
Ronald A DiCerbo McAndrews, Held & Malloy
Technical classification
Nice Classes
Class 5Class 10Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic reagents and contrast media for medical and pharmaceutical use; Diagnostic biomarker reagents for medical purposes; Diagnostic kits consisting primarily of diagnostic reagentsdiagnostic biomarkerscontrast media for medical and pharmaceutical use
Class 10
Diagnostic and analysis apparatus and instruments for medical and pharmaceutical usemolecular analysis apparatus and instruments for diagnostic and analysis use
Class 35
Wholesale store services and retail store services featuring apparatus and instruments for medical and surgical use; wholesale store services and retail store services featuring diagnostic and analysis apparatus and instruments for medical and pharmaceutical use
Class 42
Scientific and technological servicesresearch and design of diagnostic and analysis apparatus and instruments for medical and pharmaceutical use; scientific and technological servicesresearch and design of diagnostic kits for medical and pharmaceutical use intended for hospitals and pharmaceutical companies
Class 44
Medical analysis services for diagnostic and treatment purposes provided by medical laboratories intended for hospitals; Medical analysis services provided by medical laboratories intended for hospitals
Publications
History of USPTO decisions and trademark events.
43 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/10/2024
FIMP
FINAL DISPOSITION PROCESSED
04/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/29/2023
GPNX
NOTIFICATION PROCESSED BY IB
10/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/24/2023
PUBO
PUBLISHED FOR OPPOSITION
10/24/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/18/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/18/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/18/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/23/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/21/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/21/2023
CNSL
SUSPENSION LETTER WRITTEN
03/21/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/11/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/23/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/04/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/11/2022
GNFR
FINAL REFUSAL E-MAILED
08/11/2022
CNFR
FINAL REFUSAL WRITTEN
08/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/14/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/13/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/13/2022
CHLD
CHANGE OF OWNER RECEIVED FROM IB
03/18/2022
CHLD
CHANGE OF OWNER RECEIVED FROM IB
03/04/2022
RFNT
REFUSAL PROCESSED BY IB
01/30/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/13/2022
RFRR
REFUSAL PROCESSED BY MPU
01/13/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/22/2021
CNRT
NON-FINAL ACTION WRITTEN
12/21/2021
DOCK
ASSIGNED TO EXAMINER
12/15/2021
MAFR
APPLICATION FILING RECEIPT MAILED
08/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/31/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/29/2021
Continuous trademark protection
Get notified about every new filing that threatens BIOMADVANCED DIAGNOSTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.